URINARY ANGIOTENSINOGEN EXCRETION IN NORMALS AND PATIENTS WITH TYPE II DM

正常人和 II 型糖尿病患者的尿血管紧张素原排泄

• 批准号: 8167172
• 负责人: ROBERT MUNSON CAREY
• 金额: $ 10.56万
• 依托单位: UNIVERSITY OF VIRGINIA
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-03-01 至 2013-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8167172
• 关键词: Angiotensinogen; Angiotensins; Biological Assay; Clinical Research; Complications of Diabetes Mellitus; Computer Retrieval of Information on Scientific Projects Database; Diabetes Mellitus; Diabetic Nephropathy; End stage renal failure; Excretory function; Experimental Animal Model; Funding; Grant; Human; Institution; Kidney; Measurement; Microalbuminuria; Non-Insulin-Dependent Diabetes Mellitus; Pathogenesis; Patients; Renal Tissue; Renin-Angiotensin System; Research; Research Personnel; Resources; Source; Testing; Time; United States National Institutes of Health; Urine; activity marker; diabetic; human subject; urinary

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Diabetic nephropathy is a devastating complication of diabetes mellitus and its pathogenesis remains unclear. Evidence from experimental animal models indicates that diabetes is associated with an early activation of the renal tissue renin-angiotensin system even when the systemic renin-angiotensin system is suppressed. In addition, clinical studies have shown that blockade of the renin-angiotensin system delays progression from mild to end-stage renal disease, and angiotensin blockers now constitute standard therapy in diabetic subjects with microalbuminuria. We have developed an assay for human angiotensinogen, the only known precursor of angiotensin, in human urine for the first time. This study tests whether measurement of urinary angiotensinogen can serve as a marker for the activity of the local kidney renin-angiotensin system and whether, how early and to what extent urinary angiotensinogen levels are elevated in type-2 diabetes mellitus. This study anticipates that urinary angiotensinogen measurement in diabetic human subjects can predict the extent of kidney damage and can be employed to identify subjects in whom blockade of the renin-angiotensin system would be beneficial.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 糖尿病肾病是糖尿病的严重并发症，其发病机制尚不清楚。 来自实验动物模型的证据表明，即使全身肾素-血管紧张素系统受到抑制，糖尿病也与肾组织肾素-血管紧张素系统的早期激活有关。 此外，临床研究表明，阻断肾素-血管紧张素系统可延缓从轻度到终末期肾病的进展，血管紧张素阻滞剂现已成为微量白蛋白尿糖尿病患者的标准治疗方法。 我们首次开发了一种检测人体尿液中血管紧张素原（唯一已知的血管紧张素前体）的方法。 这项研究测试了尿血管紧张素原的测量是否可以作为局部肾脏肾素-血管紧张素系统活性的标志物，以及2型糖尿病中尿血管紧张素原水平是否升高、多久升高以及升高的程度。 这项研究预计，糖尿病人类受试者的尿血管紧张素原测量可以预测肾脏损伤的程度，并可用于识别阻断肾素-血管紧张素系统对哪些受试者有益。